


CLAIMS

1. A method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma a therapeutically effective amount of a compound which is an EP₄ agonist.
2. The method of claim 1 wherein said compound is represented by the general formula I;




10

wherein hatched lines represent the α configuration, a triangle represents the β configuration, a wavy line represents either the α configuration or the β configuration and a dotted line represents the presence or absence of a double bond; A and B are independently selected from the group consisting of O, S and CH₂, provided that at least one of A or B is S;

D represents a covalent bond or CH₂, O, S or NH;

X is CO₂R, CONR₂, CH₂OR, P(O)(OR)₂, CONRSO₂R, SONR₂ or

15



Y is O, OH, OCOR^2 , halogen or cyano;

Z is CH_2 or a covalent bond;

R is H or R^2 ;


5 R^1 is H, R^2 , phenyl, or COR^2 ;

R^2 is $\text{C}_1\text{-C}_5$ lower alkyl or alkenyl;

R_3 is benzothienyl, benzofuranyl, naphthyl, or substituted derivatives thereof,
wherein the substituents maybe selected from the group consisting of $\text{C}_1\text{-C}_5$ alkyl,
halogen, CF_3 , CN, NO_2 , NR_2 , CO_2R and OR and R^4 is hydrogen or $\text{C}_1\text{-C}_5$ lower


10 alkyl.

3. The method according to claim 2 wherein said compound is represented by
the general formula II;



15

4. The method according to claim 3 wherein said compound is represented by
the general formula III;



5. The method of claim 2 wherein Z represents a covalent bond.
6. The method of claim 2 wherein D represents a covalent bond or is CH₂.
7. The method of claim 2 wherein X is CO₂ R.
8. The method of claim 7 wherein R is selected from the group consisting of H,
5 methyl, i-propyl, and n-propenyl.
9. The method of claim 2 wherein R is H, or n-propenyl.
10. The method of claim 2 wherein R₁ is H.
11. The method of claim 2 wherein D is CH₂.
12. The method of claim 11 wherein R³ is benzo[b]thienyl, 3-
10 chlorobenzo[b]thienyl or naphthyl.
13. An ophthalmic solution comprising a therapeutically effective amount of a
compound which is EP₄ agonist.
- 15 14. A pharmaceutical product, comprising a container adapted to dispense the
contents of said container in metered form; and an ophthalmic solution according to
claim 13 in said container.
15. The method of claim 1 wherein said compound is GR 50209X.